diff --git a/src/main/webapp/app/config/constants.tsx b/src/main/webapp/app/config/constants.tsx
index d95031af8..0d32c0f4a 100644
--- a/src/main/webapp/app/config/constants.tsx
+++ b/src/main/webapp/app/config/constants.tsx
@@ -866,7 +866,7 @@ export type DataRelease = {
 };
 
 export const DATA_RELEASES: DataRelease[] = [
-  { date: '02302025', version: 'v4.26' },
+  { date: '02252025', version: 'v4.26' },
   { date: '01302025', version: 'v4.25' },
   { date: '12192024', version: 'v4.24' },
   { date: '11262024', version: 'v4.23' },
diff --git a/src/main/webapp/app/pages/newsPage/NewsList.tsx b/src/main/webapp/app/pages/newsPage/NewsList.tsx
index 00db26e9e..7582ee5cf 100644
--- a/src/main/webapp/app/pages/newsPage/NewsList.tsx
+++ b/src/main/webapp/app/pages/newsPage/NewsList.tsx
@@ -19,7 +19,6 @@ import HashLink from 'app/shared/links/HashLink';
 import { RouterStore } from 'mobx-react-router';
 import { observable } from 'mobx';
 import { observer } from 'mobx-react';
-import NewsContent01302025 from './code-generated/NewsContent01302025';
 
 export type NewsListProps = {
   date: string;
diff --git a/src/main/webapp/app/pages/newsPage/NewsPage.tsx b/src/main/webapp/app/pages/newsPage/NewsPage.tsx
index cd7fced2a..efe908705 100644
--- a/src/main/webapp/app/pages/newsPage/NewsPage.tsx
+++ b/src/main/webapp/app/pages/newsPage/NewsPage.tsx
@@ -86,7 +86,7 @@ export default class NewsPage extends React.Component<{
           <CitationText />
         </div>
         <div className="mt-2">
-          <NewsList date={'02282025'} />
+          <NewsList date={'02252025'} />
           <NewsList date={'01302025'} />
           <NewsList date={'12192024'} />
           <NewsList date={'11262024'} />
diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
index 442ac85f8..98c4446e3 100644
--- a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
+++ b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx
@@ -45,7 +45,7 @@ import { PMALink } from 'app/shared/links/PMALink';
 import OptimizedImage from 'app/shared/image/OptimizedImage';
 import { AnnotationColumnHeaderType } from './ChangedAnnotationListItem';
 import { linkableMutationName, convertGeneInputToLinks } from './Util';
-import NewsContent022025 from './code-generated/NewsContent022025';
+import NewsContent022025 from './code-generated/NewsContent022525';
 
 export type ChangedAnnotation = {
   content: (ElementType | ElementType[])[][];
@@ -303,7 +303,7 @@ const EVIDENCE_COLUMN_SEPARATOR = '; ';
 // https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces
 
 export const NEWS_BY_DATE: { [date: string]: NewsData } = {
-  '02282025': {
+  '02252025': {
     rawComponent: <NewsContent022025 />,
   },
   '01302025': {
diff --git a/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx b/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx
similarity index 80%
rename from src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx
rename to src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx
index 60745e394..993b7d363 100644
--- a/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022025.tsx
+++ b/src/main/webapp/app/pages/newsPage/code-generated/NewsContent022525.tsx
@@ -6,7 +6,7 @@ import {
 } from 'app/shared/utils/UrlUtils';
 import { NewlyAddedGenesListItem } from 'app/pages/newsPage/NewlyAddedGenesListItem';
 
-export default function NewsContent022025() {
+export default function NewsContent022525() {
   return (
     <>
       <ul>
@@ -39,11 +39,14 @@ export default function NewsContent022025() {
               </td>
               <td>Pancreatic Cancer</td>
               <td>
-                <em>Drug(s) promoted in OncoKB™:</em> Erdafitnib (Level 2,
-                previously Level 4)
+                <em>Drug(s) promoted in OncoKB™:</em>
                 <br />
+                Erdafitnib (Level 2, previously Level 4)
                 <br />
-                <em>Drug(s) remaining in OncoKB™:</em> Fexagratinib (Level 4)
+                <br />
+                <em>Drug(s) remaining in OncoKB™:</em>
+                <br />
+                Fexagratinib (Level 4)
               </td>
               <td>4</td>
               <td>2</td>
@@ -62,11 +65,14 @@ export default function NewsContent022025() {
               </td>
               <td>Pancreatic Cancer</td>
               <td>
-                <em>Drug(s) promoted in OncoKB™:</em> Erdafitnib (Level 2,
-                previously Level 4)
+                <em>Drug(s) promoted in OncoKB™:</em>
+                <br />
+                Erdafitnib (Level 2, previously Level 4)
+                <br />
                 <br />
+                <em>Drug(s) remaining in OncoKB™:</em>
                 <br />
-                <em>Drug(s) remaining in OncoKB™:</em> Fexagratinib (Level 4)
+                Fexagratinib (Level 4)
               </td>
               <td>4</td>
               <td>2</td>
@@ -85,12 +91,14 @@ export default function NewsContent022025() {
               </td>
               <td>Non-Small Cell Lung Cancer</td>
               <td>
-                <em>Drug(s) promoted in OncoKB™:</em> Erdafitnib (Level 2,
-                previously Level 4)
+                <em>Drug(s) promoted in OncoKB™:</em>
                 <br />
+                Erdafitnib (Level 2, previously Level 4)
                 <br />
-                <em>Drug(s) remaining in OncoKB™:</em> Fexagratinib,
-                Lirafugratinib (Level 4)
+                <br />
+                <em>Drug(s) remaining in OncoKB™:</em>
+                <br />
+                Fexagratinib, Lirafugratinib (Level 4)
               </td>
               <td>4</td>
               <td>2</td>
@@ -110,11 +118,14 @@ export default function NewsContent022025() {
               </td>
               <td>Non-Small Cell Lung Cancer</td>
               <td>
-                <em>Drug(s) promoted in OncoKB™:</em> Erdafitnib (Level 2,
-                previously Level 4)
+                <em>Drug(s) promoted in OncoKB™:</em>
+                <br />
+                Erdafitnib (Level 2, previously Level 4)
+                <br />
                 <br />
+                <em>Drug(s) remaining in OncoKB™:</em>
                 <br />
-                <em>Drug(s) remaining in OncoKB™:</em> Fexagratinib (Level 4)
+                Fexagratinib (Level 4)
               </td>
               <td>4</td>
               <td>2</td>
@@ -171,10 +182,20 @@ export default function NewsContent022025() {
           </tbody>
         </table>
       </div>
+      <h4></h4>
       <ul>
         <li>
           <NewlyAddedGenesListItem
-            genes={['ALOX5', 'APEX1', 'RPS6KB1', 'TACSTD2']}
+            genes={[
+              'ALOX5',
+              'APEX1',
+              'CBLB',
+              'DHX15',
+              'POLH',
+              'RPS6KB1',
+              'TACSTD2',
+              'WEE1',
+            ]}
           ></NewlyAddedGenesListItem>
         </li>
       </ul>
diff --git a/src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md b/src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md
similarity index 58%
rename from src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md
rename to src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md
index dfc35674a..ab3e4f10f 100644
--- a/src/main/webapp/app/pages/newsPage/markdown/NewsContent022025.md
+++ b/src/main/webapp/app/pages/newsPage/markdown/NewsContent022525.md
@@ -1,11 +1,11 @@
 - Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration
 
-| Gene  | Mutation            | Cancer Type                | Level-associated Drug(s) in OncoKB™                                                                                                                       | Previous Level | Updated Level | Evidence                                                                                                                     |
-| :---- | :------------------ | :------------------------- | :-------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- |
-| FGFR1 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
-| FGFR2 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
-| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib, Lirafugratinib (Level 4\) | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
-| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_ Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_ Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
+| Gene  | Mutation            | Cancer Type                | Level-associated Drug(s) in OncoKB™                                                                                                                               | Previous Level | Updated Level | Evidence                                                                                                                     |
+| :---- | :------------------ | :------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- |
+| FGFR1 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
+| FGFR2 | Fusions             | Pancreatic Cancer          | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/)          |
+| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib, Lirafugratinib (Level 4\) | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
+| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\)                 | 4              | 2             | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
 
 - Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
 
@@ -13,8 +13,14 @@
 | :---- | :--- | :------- | :---------------- | :---------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
 | 1     | BRAF | V600E    | Colorectal Cancer | Encorafenib \+ Cetuximab (Level 1\) | Encorafenib \+ Cetuximab \+ FOLFOX Regimen (Level 1\) | [FDA approval of encorafenib with cetuximab and mFOLFOX6](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf); PMID: [39863775](https://pubmed.ncbi.nlm.nih.gov/39863775/) |
 
-- Addition of 4 new genes:
+####
+
+- Addition of 8 new genes:
   - ALOX5
   - APEX1
+  - CBLB
+  - DHX15
+  - POLH
   - RPS6KB1
   - TACSTD2
+  - WEE1